A citation-based method for searching scientific literature

Rosario Morrugares, Alejandro Correa-Sáez, Rita Moreno, Martín Garrido-Rodríguez, Eduardo Muñoz, Laureano de la Vega, Marco A Calzado. Cell Mol Life Sci 2020
Times Cited: 10







List of co-cited articles
112 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Rei Mimoto, Naoe Taira, Hiroyuki Takahashi, Tomoko Yamaguchi, Masataka Okabe, Ken Uchida, Yoshio Miki, Kiyotsugu Yoshida. Cancer Lett 2013
53
40

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Haiyan Yan, Kaishun Hu, Wenjing Wu, Yu Li, Huan Tian, Zhonghua Chu, H Phillip Koeffler, Dong Yin. PLoS One 2016
20
40


Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Sourav Banerjee, Tiantian Wei, Jue Wang, Jenna J Lee, Haydee L Gutierrez, Owen Chapman, Sandra E Wiley, Joshua E Mayfield, Vasudha Tandon, Edwin F Juarez,[...]. Proc Natl Acad Sci U S A 2019
20
40

Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Shin-ichi Yamashita, Masao Chujo, Keita Tokuishi, Kentaro Anami, Michiyo Miyawaki, Satoshi Yamamoto, Katsunobu Kawahara. J Thorac Cardiovasc Surg 2009
12
40

Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.
Pamela A Lochhead, Gary Sibbet, Nick Morrice, Vaughn Cleghon. Cell 2005
209
40


ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.
Naoe Taira, Hiroyuki Yamamoto, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. J Biol Chem 2010
50
40

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
R Mimoto, Y Imawari, S Hirooka, H Takeyama, K Yoshida. Oncogene 2017
19
40

The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.
Paula Moreno, Maribel Lara-Chica, Rafael Soler-Torronteras, Teresa Caro, Manuel Medina, Antonio Álvarez, Ángel Salvatierra, Eduardo Muñoz, Marco A Calzado. PLoS One 2015
13
40

DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.
Naoe Taira, Keishi Nihira, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. Mol Cell 2007
205
40

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Xing Guo, Xiaorong Wang, Zhiping Wang, Sourav Banerjee, Jing Yang, Lan Huang, Jack E Dixon. Nat Cell Biol 2016
102
40

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Naoe Taira, Rei Mimoto, Morito Kurata, Tomoko Yamaguchi, Masanobu Kitagawa, Yoshio Miki, Kiyotsugu Yoshida. J Clin Invest 2012
92
40

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
Meera Soundararajan, Annette K Roos, Pavel Savitsky, Panagis Filippakopoulos, Arminja N Kettenbach, Jesper V Olsen, Scott A Gerber, Jeyanthy Eswaran, Stefan Knapp, Jonathan M Elkins. Structure 2013
95
40

Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.
Hae-Yun Jung, Xin Wang, Sohee Jun, Jae-Il Park. J Biol Chem 2013
45
40


DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Noriko Yamaguchi, Rei Mimoto, Nozomu Yanaihara, Yoshimi Imawari, Shinichi Hirooka, Aikou Okamoto, Kiyotsugu Yoshida. Tumour Biol 2015
28
30

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.
Yousang Gwack, Sonia Sharma, Julie Nardone, Bogdan Tanasa, Alina Iuga, Sonal Srikanth, Heidi Okamura, Diana Bolton, Stefan Feske, Patrick G Hogan,[...]. Nature 2006
285
30

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Yuchan Wang, Yaxun Wu, Xiaobing Miao, Xinghua Zhu, Xianjing Miao, Yunhua He, Fei Zhong, Linlin Ding, Jing Liu, Jie Tang,[...]. Int J Biol Macromol 2015
11
30

Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy.
Shunichiro Nomura, Yasutomo Suzuki, Ryo Takahashi, Mika Terasaki, Ryoji Kimata, Yasuhiro Terasaki, Tsutomu Hamasaki, Go Kimura, Akira Shimizu, Yukihiro Kondo. BMC Urol 2015
17
30

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Daisuke Ito, Satomi Yogosawa, Rei Mimoto, Shinichi Hirooka, Takashi Horiuchi, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Cancer Sci 2017
20
30

Multiple functions of DYRK2 in cancer and tissue development.
Saishu Yoshida, Kiyotsugu Yoshida. FEBS Lett 2019
18
30

Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Yasuko Enomoto, Shin-ichi Yamashita, Yasuteru Yoshinaga, Yasuyoshi Fukami, So Miyahara, Kazuki Nabeshima, Akinori Iwasaki. Tumour Biol 2014
23
30

Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
Xiubing Zhang, Pan Xu, Wenkai Ni, Hui Fan, Jian Xu, Yongmei Chen, Wei Huang, Shumin Lu, Li Liang, Jinxia Liu,[...]. Pathol Res Pract 2016
24
30

Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo.
Adam R Cole, Frédéric Causeret, Gokhan Yadirgi, C James Hastie, Hilary McLauchlan, Edward J McManus, Félix Hernández, Britta J Eickholt, Margareta Nikolic, Calum Sutherland. J Biol Chem 2006
173
30

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Yasushi Ogawa, Yosuke Nonaka, Toshiyasu Goto, Eriko Ohnishi, Toshiyuki Hiramatsu, Isao Kii, Miyo Yoshida, Teikichi Ikura, Hiroshi Onogi, Hiroshi Shibuya,[...]. Nat Commun 2010
175
30

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Nora Göckler, Guillermo Jofre, Chrisovalantis Papadopoulos, Ulf Soppa, Francisco J Tejedor, Walter Becker. FEBS J 2009
165
30

Regulation of Glioma Cells Migration by DYRK2.
Yifen Shen, Li Zhang, Donglin Wang, Yifeng Bao, Chao Liu, Zhiwei Xu, Wei Huang, Chun Cheng. Neurochem Res 2017
8
37

A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Chun Shik Park, Andrew H Lewis, Taylor J Chen, Cory S Bridges, Ye Shen, Koramit Suppipat, Monica Puppi, Julie A Tomolonis, Paul D Pang, Toni-Ann Mistretta,[...]. Blood 2019
26
30

Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Tomotaka Kumamoto, Kohji Yamada, Saishu Yoshida, Katsuhiko Aoki, Shinichi Hirooka, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Int J Oncol 2020
10
30

DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding.
Mónica Alvarez, Xavier Altafaj, Sergi Aranda, Susana de la Luna. Mol Biol Cell 2007
52
30

Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways.
Moisés Pérez, Carmen García-Limones, Inés Zapico, Anabel Marina, M Lienhard Schmitz, Eduardo Muñoz, Marco A Calzado. J Mol Cell Biol 2012
43
30

Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Charles T Miller, Sanjeev Aggarwal, Theodore K Lin, Susan L Dagenais, Jorge I Contreras, Mark B Orringer, Thomas W Glover, David G Beer, Lin Lin. Cancer Res 2003
44
30

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Shiho Yokoyama-Mashima, Satomi Yogosawa, Yumi Kanegae, Shinichi Hirooka, Saishu Yoshida, Takashi Horiuchi, Toya Ohashi, Katsuhiko Yanaga, Masayuki Saruta, Tsunekazu Oikawa,[...]. Cancer Lett 2019
16
30

Characterization of a domain that transiently converts class 2 DYRKs into intramolecular tyrosine kinases.
Ross Kinstrie, Nathan Luebbering, Diego Miranda-Saavedra, Gary Sibbet, Jingfen Han, Pamela A Lochhead, Vaughn Cleghon. Sci Signal 2010
30
30

Specificity determinants of substrate recognition by the protein kinase DYRK1A.
S Himpel, W Tegge, R Frank, S Leder, H G Joost, W Becker. J Biol Chem 2000
181
30

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Anne L Ashford, Tom P J Dunkley, Mark Cockerill, Rachel A Rowlinson, Lisa M Baak, Raffaella Gallo, Kathryn Balmanno, Louise M Goodwin, Richard A Ward, Pamela A Lochhead,[...]. Cell Mol Life Sci 2016
13
30

Cep78 controls centrosome homeostasis by inhibiting EDD-DYRK2-DDB1VprBP.
Delowar Hossain, Yalda Javadi Esfehani, Arindam Das, William Y Tsang. EMBO Rep 2017
26
30

p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation That Is Required for GSK3β-βTrCP-Induced Snail Degradation.
Ki-Jun Ryu, Sun-Mi Park, Seung-Ho Park, In-Kyu Kim, Hyeontak Han, Hyo-Jin Kim, Seon-Hee Kim, Keun-Seok Hong, Hyemin Kim, Minju Kim,[...]. Cancer Res 2019
18
30

DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Shin-ichi Yamashita, Masao Chujo, Toshihiko Moroga, Kentaro Anami, Keita Tokuishi, Michiyo Miyawaki, Yozo Kawano, Shinsuke Takeno, Satoshi Yamamoto, Katsunobu Kawahara. Anticancer Res 2009
26
30

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Sourav Banerjee, Chenggong Ji, Joshua E Mayfield, Apollina Goel, Junyu Xiao, Jack E Dixon, Xing Guo. Proc Natl Acad Sci U S A 2018
65
30

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, Martín Garrido-Rodríguez, Rosario Morrugares, Eduardo Muñoz, Marco A Calzado. Cell Mol Life Sci 2020
11
30

The selectivity of protein kinase inhibitors: a further update.
Jenny Bain, Lorna Plater, Matt Elliott, Natalia Shpiro, C James Hastie, Hilary McLauchlan, Iva Klevernic, J Simon C Arthur, Dario R Alessi, Philip Cohen. Biochem J 2007
30

FBXW7: a critical tumor suppressor of human cancers.
Chien-Hung Yeh, Marcia Bellon, Christophe Nicot. Mol Cancer 2018
204
30


Therapeutic modulation of Notch signalling--are we there yet?
Emma R Andersson, Urban Lendahl. Nat Rev Drug Discov 2014
319
30

Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.
Nicholas J Wang, Zachary Sanborn, Kelly L Arnett, Laura J Bayston, Wilson Liao, Charlotte M Proby, Irene M Leigh, Eric A Collisson, Patricia B Gordon, Lakshmi Jakkula,[...]. Proc Natl Acad Sci U S A 2011
316
30

Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.
Vassilios Myrianthopoulos, Marina Kritsanida, Nicolas Gaboriaud-Kolar, Prokopios Magiatis, Yoan Ferandin, Emilie Durieu, Olivier Lozach, Daniel Cappel, Meera Soundararajan, Panagis Filippakopoulos,[...]. ACS Med Chem Lett 2013
49
20

Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Gregory D Cuny, Natalia P Ulyanova, Debasis Patnaik, Ji-Feng Liu, Xiangjie Lin, Ken Auerbach, Soumya S Ray, Jun Xian, Marcie A Glicksman, Ross L Stein,[...]. Bioorg Med Chem Lett 2012
42
20

Interaction between RNF8 and DYRK2 is required for the recruitment of DNA repair molecules to DNA double-strand breaks.
Takenori Yamamoto, Naoe Taira Nihira, Satomi Yogosawa, Katsuhiko Aoki, Hiroyuki Takeda, Tatsuya Sawasaki, Kiyotsugu Yoshida. FEBS Lett 2017
13
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.